Analysis of Biopsy Results at 36 Months After Permanent I-125 Implantation Therapy Plus LHRH-agonist Therapy for Patients With Untreated Intermediate Prostate Cancer.
- To analyze biopsy results at 36 months after permanent iodine I 125 implantation
therapy and luteinizing hormone-releasing hormone (LHRH) agonist therapy for patients
with untreated intermediate-risk prostate cancer.
OUTLINE: Patients received luteinizing hormone releasing-hormone (LHRH) agonist therapy and
permanent iodine I 125 implantation on protocol JUSMH-BRI-GU05-01.
Patients undergo blood sample collection and tissue biopsy for biomarker/laboratory analysis
at 36 months after receiving brachytherapy and releasing-hormone agonist therapy. PSA levels
and biopsy results are compared.
Comparison of PSA levels and biopsy results at 36 months
Shin Egawa, MD, PhD
Jikei University School of Medicine